Devises / IMCR
IMCR: Immunocore Holdings plc - American Depositary Shares
32.34
USD
0.03
(0.09%)
Le taux de change de IMCR a changé de 0.09% aujourd'hui. Au cours de la journée, l'instrument a été échangé à un minimum de 31.37 et à un maximum de 33.00.
Suivez la dynamique Immunocore Holdings plc - American Depositary Shares. Les cotations en temps réel vous aideront à réagir rapidement aux changements du marché. En basculant entre différentes périodes, vous pouvez surveiller les tendances et la dynamique des taux de change par minutes, heures, jours, semaines et mois. Utilisez ces informations pour prévoir les changements du marché et prendre des décisions de trading éclairées.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
IMCR Nouvelles
- Seeking Alpha Immunocore Holdings plc 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:IMCR)
- Seeking Alpha Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript
- Zacks IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
- Zacks Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
- Zacks Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
- Zacks PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
- Zacks MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
- Zacks Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
- Zacks Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
- Zacks Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
- Zacks Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics
- Zacks ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
- Investing Immunocore Holdings earnings missed by $0.02, revenue topped estimates
- Zacks Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
- Zacks HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
- Zacks BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
- Zacks RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
- Zacks Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
- Zacks ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
- Zacks Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut
- Zacks JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
- Zacks ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
- Zacks TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
- Zacks CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
Range quotidien
31.37
33.00
Range Annuel
23.15
39.32
- Clôture Précédente
- 32.31
- Ouverture
- 32.29
- Bid
- 32.34
- Ask
- 32.64
- Plus Bas
- 31.37
- Plus Haut
- 33.00
- Volume
- 641
- Changement quotidien
- 0.09%
- Changement Mensuel
- -1.88%
- Changement à 6 Mois
- 7.76%
- Changement Annuel
- -8.95%
19 août, mardi
12:30
USD
- Act
- 1.428 M
- Fcst
- 1.287 M
- Prev
- 1.358 M
12:30
USD
- Act
- 1.354 M
- Fcst
- 1.415 M
- Prev
- 1.393 M
12:30
USD
- Act
- 5.2%
- Fcst
- 3.2%
- Prev
- 5.9%
12:30
USD
- Act
- -2.8%
- Fcst
- -1.8%
- Prev
- -0.1%
18:10
USD
- Act
- Fcst
- Prev